Recent reports suggest that activating genomic alterations in KRAS, EGFR, and ALK, as well as loss of PTEN, possess the potential to biologically influence PD‐L1 expression in NSCLC.8, 11, 12, 13. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.